With likely competition to come for one drug, Aegerion buys another for $325M
November 06, 2014 at 13:06 PM EST
Cambridge drug company Aegerion, whose only drug on the market could soon face competition from Amgen, has purchased an approved rare disease drug from AstraZeneca for $325 million...